Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27252890 | 0.87 | OPRM1 (0.38) | OPRM1TSHRALDH1A1 | |
| SCHEMBL17202686 | 0.82 | METAP1 (0.38) | METAP1MMP9OPRM1TSHRALDH1A1 | |
| SCHEMBL24352948 | 0.82 | — | — | |
| SCHEMBL8367717 | 0.78 | MMP9 (0.36) | METAP1MMP9TSHRALDH1A1 | |
| SCHEMBL27234546 | 0.77 | METAP1 (0.33) | METAP1OPRM1 | |
| SCHEMBL5132479 | 0.76 | — | — | |
| SCHEMBL24547712 | 0.75 | METAP1 (0.46) | METAP1OPRM1TSHRALDH1A1 | |
| SCHEMBL19117382 | 0.75 | METAP1 (0.46) | METAP1OPRM1TSHRALDH1A1 | |
| SCHEMBL10257986 | 0.74 | METAP1 (0.35) | METAP1MMP9TSHR | |
| SCHEMBL15540193 | 0.74 | OPRM1 (0.38) | OPRM1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193251-A1 | CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | TUBB6, GALNT10, TUBB | METAP1 1678/4885MMP9 4715/4885OPRM1 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.